Stanford researchers in Prof. Engleman and Reticker-Flynn's labs have created a novel cell therapy that targets the T-antigen, a prominent tumor-specific antigen, by leveraging the high avidity interactions between lectins and glycans.
Overweight and obesity are linked to an increased risk and worsened outcome from many cancers, including colorectal, pancreatic and breast cancer, but the mechanisms responsible for these phenomena are unknown.
Stanford researchers have defined subgroups of regulatory T cell (Tregs), CD39+ and CD39-, that can be genetically engineered to produce enhanced or reduced cytotoxicity without affecting their ability to suppress the immune system.
Scientists in the Carette Lab at Stanford have developed AAV-Titer cell lines that enable (1) improved and standardized in vitro potency assays (2) determination of a functional titer of AAV vectors of different serotypes and containing different promotors.
Researchers at Stanford have developed a computational tool that enables the discovery of regenerative cells across all tissue types and novel targets in cancer.
Stanford researchers have developed tissue-based profiling by deep sequencing for detection of Minimal Residual Disease (MRD) by tracking patient-specific tumor mutations in post-chemotherapy tissue samples, enabling a highly sensitive, molecular-level assessment of residual c
Researchers at Stanford have developed fusion proteins, containing ACE2 domain linked to a fragment of non-neutralizing anti-SARS-CoV-2 spike protein antibody, with a greater breadth of protection than previously described similar fusion proteins.
Stanford researchers have invented a twist-expand mechanical bioreactor that provides an appropriate in vitro microenvironment for induced pluripotent stem cell (iPSC) derived cardiomyocytes to achieve biomimetic anisotropic alignment and form contractile cardiac tissue
Stanford researchers have engineered hematopoietic stem cells to provide long-term secretion of chosen therapeutic antibodies, eliminating the need of repeated dosing for delivery.
Researchers at Stanford University have developed a novel kidney stone extraction device that can be used during ureteroscopy to simultaneously remove kidney stone fragments and dust without affecting renal pressure.
Stanford scientists have developed PVSeg, a tool that automatically segments vascular and perivascular compartments in brain MRI data. This innovative tool can identify non-demented individuals at increased risk of developing dementia and accelerated brain atrophy.
Researchers in Dr. Michelle Monje-Deisseroth's lab at Stanford have identified therapeutic targets for drug development to limit the spread of high-grade gliomas (HGGs).
Stanford scientists have developed a device to distinguish the molecule-specific signatures of diseased exosomes isolated from glioblastoma patients. The device is portable, disposable, and low-cost, enabling point-of-care assessment of disease.